Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Covalon Technologies Ltd V.COV

Alternate Symbol(s):  CVALF

Covalon Technologies Ltd. is a patient-driven medical device company. Through a portfolio of patented technologies and solutions for advanced wound care, infection prevention, and medical device coatings, the Company offers gentler and more compassionate options for patients to heal with less infections, less pain, and better outcomes. Its solutions are designed for patients and made for care... see more

TSXV:COV - Post Discussion

Covalon Technologies Ltd > Covalon to Present at the SNN Network Canada Virtual Event
View:
Post by BCONTVentures on Dec 04, 2021 9:06am

Covalon to Present at the SNN Network Canada Virtual Event

Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV:COV)(OTCQX:CVALF), an advanced medical technologies company, today announced that it will be presenting at the SNN Network Canada Virtual Event 2021 on Wednesday, December 8, 2021, at 3:30 PM EST. Brian Pedlar, Chief Executive Officer of Covalon, will be hosting the presentation and answering questions from investors.

https://ceo.ca/@accesswire/covalon-technologies-to-present-at-the-snn-network

To access the live presentation, please use the following information:

SNN Network Canada Virtual Event 2021
Date: Wednesday, December 8, 2021
Time: 3:30 PM Eastern Time
Webcast: https://www.webcaster4.com/Webcast/Page/2813/43826

Covalon is an innovation-driven medical device company, with a strong portfolio of patented dressings and technology that make it easier for health care providers to protect patients from infection and help patients heal. Whether suffering from a chronic wound, recovering from a surgery, or undergoing treatment that requires vascular insertions, patients benefit from Covalon's family of FDA approved products and technology that are designed to reduce complications during treatments.
With the recently completed sale of its AquaGuard product line, Covalon is debt free with over $24 million of cash (approximately $0.93 per share) on its balance sheet. Covalon is positioned extremely well to further accelerate the growth of its biological collagen and antimicrobial products that have been contributing to revenue growth this fiscal year.
If you would like to book 1on1 investor meetings with Covalon, and to watch Covalon's presentation, please make sure you are registered for the virtual event here:

https://canada.snn.network/signup

1on1 meetings will be scheduled and conducted via private, secure video conference through the conference event platform.
The SNN Network Canada Virtual Event website is available here:

https://canada.snn.network/

If you can't make the live presentation, all company presentations "webcasts" will be available directly on the conference event platform on this link under the tab "Agenda":

https://canada.snn.network/agenda
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities